Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?

Many dermatologists—and patients—are asking whether, during the Covid-19 pandemic, biologics such as dupilumab should be stopped in patients with AD? What are your recommendations?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Mark Lebwohl, MD

Mark Lebwohl, MD

Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York USA